IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension
Cho WK, Lee CM, Kang MJ, Huang Y, Giordano FJ, Lee PJ, Trow TK, Homer RJ, Sessa WC, Elias JA, Lee CG. IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2012, 304: l112-l124. PMID: 23125252, PMCID: PMC3543640, DOI: 10.1152/ajplung.00101.2012.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionIL-13Human pulmonary artery smooth muscle cellsDevelopment of PHPulmonary artery smooth muscle cellsRight ventricle systolic pressurePathogenesis of PHArtery smooth muscle cellsExpression of ARG2Pulmonary arterial hypertensionPulmonary vascular remodelingVentricle systolic pressurePotential therapeutic targetIL-13 treatmentSmooth muscle cellsNull mutant miceArterial hypertensionEffector cytokinesMedial thickeningSystolic pressureHemodynamic changesPulmonary arterySmall-interfering RNAVascular remodelingArginase-2Targeted approaches to the treatment of pulmonary hypertension
Fares WH, Trow TK. Targeted approaches to the treatment of pulmonary hypertension. Therapeutic Advances In Respiratory Disease 2012, 6: 147-159. PMID: 22438264, DOI: 10.1177/1753465812441849.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionHigh-dose calcium channel blockersChest Physicians criteriaMultiple therapeutic optionsDurability of responseCalcium channel blockersTransplant evaluationPulmonary hypertensionOral therapyClose followPhysician's criteriaTherapeutic optionsChannel blockersEarly initiationAmerican CollegeHigh riskPatientsIncurable diseaseHypertensionEarly useStatus benefitsTreatmentDiseaseProgression